KCNU1
ENSG00000215262
Target class
Ion channel
Chromosome
8
- Chemical probe available
- No
- Target name
- KCNU1
- Gene name
- Potassium calcium-activated channel subfamily U member 1
- Gene symbol
- KCNU1
- Protein name
- Potassium channel subfamily U member 1 (Calcium-activated potassium channel subunit alpha-3) (Calcium-activated potassium channel, subfamily M subunit alpha-3) (KCa5) (Slowpoke homolog 3)
- KCa5.1
- Slo3
- KCNMC1
- Kcnma3
- Gene biotype
- Protein coding
- Gene family
- Potassium calcium-activated channels
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 1
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 11.96
- Tissue specificity (Gini)
- 0.978
- Tissue specificity (tau)
- 1
- KEGG gene identifiers
- hsa:157855
- Reactome pathways
- R-HSA-1300642
- Protein interaction confidence
- 0.87065
- Protein interaction partners
- 20
- End position
- 36936125
- Start position
- 36784324
- Chromosome
- 8
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein . Cell projection, cilium, flagellum membrane
- Multi-pass membrane protein .
- Plasma membrane
- Principal piece
- PubMed 24670955
- PubMed 38267364
- Tissue specificity (tau)
- 0.999574
- Expression inequality (Gini)
- 0.978029
Expression in transcripts per million
- Testis
- 11.96
- Prostate
- 0.07
- Skin - Not Sun Exposed (Suprapubic)
- 0.04
- Cells - Cultured fibroblasts
- 0.03
- Skin - Sun Exposed (Lower leg)
- 0.02
Expression in transcripts per million
- Testis11.96
- Prostate0.07
- Skin - Not Sun Exposed (Suprapubic)0.04
- Cells - Cultured fibroblasts0.03
- Skin - Sun Exposed (Lower leg)0.02
- Brain - Substantia nigra0.02
- Pituitary0.02
- Adipose - Subcutaneous0.02
- Breast - Mammary Tissue0.02
- Esophagus - Mucosa0.01
- Brain - Spinal cord (cervical c-1)0.01
- Brain - Hypothalamus0.01
- Heart - Atrial Appendage0
- Fallopian Tube0
- Small Intestine - Terminal Ileum0
- Cells - EBV-transformed lymphocytes0
- Liver0
- Brain - Cerebellar Hemisphere0
- Brain - Hippocampus0
- Esophagus - Gastroesophageal Junction0
- Brain - Amygdala0
- Cervix - Endocervix0
- Cervix - Ectocervix0
- Brain - Frontal Cortex (BA9)0
- Bladder0
And 29 more, listed on the interactive page.
- GO:0022414
- GO:0071805
- GO:0005886
- GO:0036126
Molecular functions
- GO:0005267
Related records
Trials (39)
- A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)
- A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
- A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
- A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
- A Phase 1 Study Comparing AVP-786 With AVP-923
- A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects
- A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers
- A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers
- A Study of Imlunestrant (LY3484356) in Female Healthy Participants
- A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants
- A Study to Evaluate the Effect of Genotype on LY2216684
- A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.
- A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine
- Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
- Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
- Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)
- Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)
- Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts
- Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.
- Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers